2019 Future of Obsessive Compulsive Disorder (OCD) R&D Pipeline Drugs and Companies- Analysis of Pipeline Compounds, Phases, Mechanism of Action, Clinical Trials and Developments

February 2019 | 40 pages | ID: 28F63FE681FEN
VPAResearch

Abstracts

The global demand for Obsessive Compulsive Disorder (OCD) treatment options is emerging rapidly driven by demand in major emerging and developed markets. An increasing number of companies are working on Obsessive Compulsive Disorder (OCD) pipeline. Companies quickly adapting to the new technologies both independently and through collaborations and advancing their pipeline candidates to advanced phases will evolve as top performers. However, challenges of completing clinical trials on schedules and limited financial support are holding some of the Obsessive Compulsive Disorder (OCD) pipeline companies from advancing their products into Phase 3 or Phase 4.

Obsessive Compulsive Disorder (OCD) Report Description-

The 2019 pipeline study on Obsessive Compulsive Disorder (OCD) pipeline is a comprehensive research on the drug candidates across different phases. This research study evaluates each of the pipeline products in terms of their current status, regulatory progress and expected phase completion date. Focusing on the factors driving and challenging pipeline drug development, this strategic analysis review presents detailed analysis on all active Obsessive Compulsive Disorder (OCD) pipeline compounds.

The Obsessive Compulsive Disorder (OCD) pipeline guide presents information on all active drugs currently being developed for Obsessive Compulsive Disorder (OCD). The research work provides details of active therapeutic candidates in different phases including discovery, research, pre-clinical, phase I, Phase II, Phase III and pre-registration phases.

Details of current status, R&D progress and latest developments for every Obsessive Compulsive Disorder (OCD) pipeline candidate are analyzed.

Further, current phase of development, mechanism of drug action, special designations such as orphan drug status, fast track designation, grants awarded, etc are presented for all Obsessive Compulsive Disorder (OCD) drug candidates.

Drug development companies, collaborators, originating companies, license providers and universities participating in the Obsessive Compulsive Disorder (OCD) product pipeline are provided. Company overview, snapshot and developments are provided for all participating companies.

The report assists in identifying potential upcoming companies and drugs in Obsessive Compulsive Disorder (OCD) pipeline market along with progress of each drug. It also enables users to formulate effective strategies to stay ahead of competition.

VPA Research has developed a robust methodology for assessing pharmaceutical drugs, market sizes and sound forecast tools. All our research reports are provided through intense and repetitive primary and secondary research methods. Further, these reports are validated with industry experts to ensure reliability in the current scenario. The report is presented in a user-friendly format and presents clear and actionable insights.

Scope of Obsessive Compulsive Disorder (OCD) pipeline report includes-

• An overview of Obsessive Compulsive Disorder (OCD) disease including symptoms, causes, diagnosis and available treatment options is provided.
• Snapshot of pipeline detailing number of active compounds, mergers and acquisitions, phase wise compounds, target areas, mechanism of action, trials etc
• Phase wise count of Obsessive Compulsive Disorder (OCD) pipeline
• Company wise list of Obsessive Compulsive Disorder (OCD) pipeline
• Mechanism of Action wise Obsessive Compulsive Disorder (OCD) pipeline
• For each pipeline candidate, the following details are provided
• Snapshot (Drug, Mechanism of Action, Phase, Co Developer, Originator, Synonym, Orphan Drug Status, New Molecular Entity, Area)
• Current status of development
• Drug overview
• Mechanism of Action
• Pre-clinical and Clinical Trials/Results
• Company Overview and Recent Developments

REASONS TO BUY

• The report is designed to help industry executives promote the success and continued growth of their organizations
• Get clear understanding of the entire Obsessive Compulsive Disorder (OCD) pipeline, with details on active projects
• Stay ahead of the competition through comprehensive knowledge of Obsessive Compulsive Disorder (OCD) pipeline progress
• Get in detail information of each product with updated information on each project along with key milestones
• Gain clear insights into companies participating in Obsessive Compulsive Disorder (OCD) pipeline along with progress of each of the company’s products and information on associations/collaborations/licensing data
• Get trial information for each pipeline product under development
• Understand the pipeline structure in terms of mechanism of Action, phase and company

The report will be delivered in 2 working days.

Contents

1. TABLE OF CONTENTS

1.1 List of Tables
1.2 List of Figures

2. GLOBAL OBSESSIVE COMPULSIVE DISORDER (OCD) PIPELINE OVERVIEW

2.1 Key Findings, 2019
2.2 Disease Overview
2.3 Research Methodology

3. EXECUTIVE SUMMARY

3.1 Obsessive Compulsive Disorder (OCD) Drugs under active development, H1- 2019
3.2 Pipeline Drugs in Early Stage of Development
  3.2.1 Pre-clinical
  3.2.2 Discovery
  3.2.3 Phase
  3.2.4Phase
3.3 Pipeline Drugs in Advanced Stage of Development
  3.3.1 Phase
  3.3.2 Pre-registration
3.4 Companies involved in Obsessive Compulsive Disorder (OCD) pipeline, H1- 2019
3.5 Mechanism of Action wise Obsessive Compulsive Disorder (OCD) Pipeline Candidates

4 ADDEX THERAPEUTICS LTD OBSESSIVE COMPULSIVE DISORDER(OCD) PIPELINE DETAILS

4.1 Addex Therapeutics Ltd Business Profile
4.2 Addex Therapeutics Ltd Obsessive Compulsive Disorder(OCD) Drug Details
4.3 Drug Snapshot
  4.3.1 Originator
  4.3.2 Collaborator/Co-Developer
  4.3.3 Route of Administration
  4.3.4 Orphan Drug/Fast Track/Special Designation
  4.3.5 Geography
  4.3.6 Type of Molecular Entity
  4.3.7 Current Status
4.4 Drug Overview
4.5 Drug Mechanism of Action
4.6 Clinical/Pre-clinical Trial Details
4.7 Latest Drug Developments

5 BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD OBSESSIVE COMPULSIVE DISORDER(OCD) PIPELINE DETAILS

5.1 Biohaven Pharmaceutical Holding Company Ltd Business Profile
5.2 Biohaven Pharmaceutical Holding Company Ltd Obsessive Compulsive Disorder(OCD) Drug Details
5.3 Drug Snapshot
  5.3.1 Originator
  5.3.2 Collaborator/Co-Developer
  5.3.3 Route of Administration
  5.3.4 Orphan Drug/Fast Track/Special Designation
  5.3.5 Geography
  5.3.6 Type of Molecular Entity
  5.3.7 Current Status
5.4 Drug Overview
5.5 Drug Mechanism of Action
5.6 Clinical/Pre-clinical Trial Details
5.7 Latest Drug Developments

6 OMEROS CORPORATION OBSESSIVE COMPULSIVE DISORDER(OCD) PIPELINE DETAILS

6.1 Omeros Corporation Business Profile
6.2 Omeros Corporation Obsessive Compulsive Disorder(OCD) Drug Details
6.3 Drug Snapshot
  6.3.1 Originator
  6.3.2 Collaborator/Co-Developer
  6.3.3 Route of Administration
  6.3.4 Orphan Drug/Fast Track/Special Designation
  6.3.5 Geography
  6.3.6 Type of Molecular Entity
  6.3.7 Current Status
6.4 Drug Overview
6.5 Drug Mechanism of Action
6.6 Clinical/Pre-clinical Trial Details
6.7 Latest Drug Developments

7 PHYTECS OBSESSIVE COMPULSIVE DISORDER(OCD) PIPELINE DETAILS

7.1 Phytecs Business Profile
7.2 Phytecs Obsessive Compulsive Disorder(OCD) Drug Details
7.3 Drug Snapshot
  7.3.1 Originator
  7.3.2 Collaborator/Co-Developer
  7.3.3 Route of Administration
  7.3.4 Orphan Drug/Fast Track/Special Designation
  7.3.5 Geography
  7.3.6 Type of Molecular Entity
  7.3.7 Current Status
7.4 Drug Overview
7.5 Drug Mechanism of Action
7.6 Clinical/Pre-clinical Trial Details
7.7 Latest Drug Developments

8 RUGEN THERAPEUTICS OBSESSIVE COMPULSIVE DISORDER(OCD) PIPELINE DETAILS

8.1 Rugen Therapeutics Business Profile
8.2 Rugen Therapeutics Obsessive Compulsive Disorder(OCD) Drug Details
8.3 Drug Snapshot
  8.3.1 Originator
  8.3.2 Collaborator/Co-Developer
  8.3.3 Route of Administration
  8.3.4 Orphan Drug/Fast Track/Special Designation
  8.3.5 Geography
  8.3.6 Type of Molecular Entity
  8.3.7 Current Status
8.4 Drug Overview
8.5 Drug Mechanism of Action
8.6 Clinical/Pre-clinical Trial Details
8.7 Latest Drug Developments

9 SAVANT HWP INC OBSESSIVE COMPULSIVE DISORDER(OCD) PIPELINE DETAILS

9.1 Savant HWP Inc Business Profile
9.2 Savant HWP Inc Obsessive Compulsive Disorder(OCD) Drug Details
9.3 Drug Snapshot
  9.3.1 Originator
  9.3.2 Collaborator/Co-Developer
  9.3.3 Route of Administration
  9.3.4 Orphan Drug/Fast Track/Special Designation
  9.3.5 Geography
  9.3.6 Type of Molecular Entity
  9.3.7 Current Status
9.4 Drug Overview
9.5 Drug Mechanism of Action
9.6 Clinical/Pre-clinical Trial Details
9.7 Latest Drug Developments

10 SEROPEUTICS LLC OBSESSIVE COMPULSIVE DISORDER(OCD) PIPELINE DETAILS

10.1 Seropeutics LLC Business Profile
10.2 Seropeutics LLC Obsessive Compulsive Disorder(OCD) Drug Details
10.3 Drug Snapshot
  10.3.1 Originator
  10.3.2 Collaborator/Co-Developer
  10.3.3 Route of Administration
  10.3.4 Orphan Drug/Fast Track/Special Designation
  10.3.5 Geography
  10.3.6 Type of Molecular Entity
  10.3.7 Current Status
10.4 Drug Overview
10.5 Drug Mechanism of Action
10.6 Clinical/Pre-clinical Trial Details
10.7 Latest Drug Developments

11. LATEST OBSESSIVE COMPULSIVE DISORDER (OCD) DRUG PIPELINE DEVELOPMENTS, 2019

12. APPENDIX

12.1 About Us
12.2 Sources and Methodology
12.3 Contact Information